Overview
The CYP2C19 gene encodes one of the most clinically actionable enzymes in the human liver from the cytochrome P450 superfamily. It processes roughly 10 to 15 percent of all commonly prescribed medications, including the antiplatelet drug clopidogrel, proton pump inhibitors (omeprazole, pantoprazole), selective serotonin reuptake inhibitors (citalopram, escitalopram, sertraline), and antifungals like voriconazole.
Depending on inherited star alleles, individuals range from Poor Metabolizers to Ultrarapid Metabolizers—a cornerstone of modern clinical pharmacogenetics.
10q23.33 (Chromosome 10)
Detoxification & Pharmacogenetics
Phase I Hepatic Enzyme (Oxidation)
Drug activation & hepatic clearance
Function of CYP2C19
In Phase I hepatic metabolism, CYP2C19 either breaks down active drugs so the body can clear them safely, or converts inactive prodrugs (such as clopidogrel) into their active therapeutic form.
Key Aspects:
🐌 Loss-of-Function (*2 / rs4244285)
Two non-functional copies prevent clopidogrel activation after coronary stenting, increasing thrombotic risk, while elevating blood levels of SSRIs like citalopram.
⚡ Ultrarapid (*17 / rs12248560)
Heightened transcription clears acid-suppressing PPIs or antidepressants so rapidly that standard doses may fail to achieve therapeutic blood concentrations.
🧬 Genetic Variants (SNPs)
Two hallmark polymorphisms determine most European and global CYP2C19 metabolizer phenotypes:
10:94781859
Creates an aberrant splice site resulting in non-functional protein; severely reduces clopidogrel activation and slows SSRI breakdown.
~15% (Europe), ~30% (East Asia)
10:94761900
Increases promoter binding and enzyme output, accelerating clearance of PPIs, escitalopram, and voriconazole.
~21% (Europe)
Practical Significance
✅ Strategies & Guidance
- Pre-Treatment Cardiology Review: Share known *2/*2 or *1/*2 status before starting clopidogrel post-stent or stroke.
- Targeted SSRI Dosing: Physicians may adjust citalopram, escitalopram, or sertraline doses or choose non-CYP2C19 options.
- Medication Interaction Awareness: Inhibitors such as omeprazole or fluvoxamine can phenoconvert a normal metabolizer into a slower state.
⚠️ Clinical Notes & Risks
- Reduced Antiplatelet Protection: Inadequate clopidogrel bioactivation raises cardiovascular event risk.
- SSRI Side Effects (PM): Higher risk of QT prolongation or nausea on standard citalopram doses.
- Treatment Failure (UM): Underdosing in severe reflux or H. pylori eradication regimens with PPIs.
📚 Data Sources
- OMIM: #124020 (Cytochrome P450, Subfamily IIC, Polypeptide 19)
- dbSNP: rs4244285 (*2), rs12248560 (*17)
- CPIC Guideline: CYP2C19 Genotype and Clopidogrel / SSRI Therapy
- PharmGKB: Clinical Annotations Level 1A for CYP2C19
Last Update: November 2026
Related Research Guides for CYP2C19
Related Genes in Detoxification
GSTP1
GSTP1 is an important detoxification enzyme that neutralizes toxins and drugs by binding them to glutathione....
NAT2
NAT2 drives Phase II liver acetylation of drugs (isoniazid, sulfonamides) and heterocyclic amines. Variants divide individuals…
SLCO1B1
SLCO1B1 (OATP1B1) imports statin cholesterol drugs and bilirubin from blood into liver cells. The *5 variant…